Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17054108rdf:typepubmed:Citationlld:pubmed
pubmed-article:17054108lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C1556084lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C0024501lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C0278601lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:17054108lifeskim:mentionsumls-concept:C1510810lld:lifeskim
pubmed-article:17054108pubmed:issue11lld:pubmed
pubmed-article:17054108pubmed:dateCreated2006-11-27lld:pubmed
pubmed-article:17054108pubmed:abstractTextThe authors evaluated the long-term efficacy and side effects in patients with nonmetastatic, unilateral, inflammatory breast cancer (IBC) who received homogeneous treatment with intensive induction chemotherapy followed by a maintenance regimen.lld:pubmed
pubmed-article:17054108pubmed:languageenglld:pubmed
pubmed-article:17054108pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17054108pubmed:statusMEDLINElld:pubmed
pubmed-article:17054108pubmed:monthDeclld:pubmed
pubmed-article:17054108pubmed:issn0008-543Xlld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:CholletPhilip...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:FumoleauPierr...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:MerroucheYaci...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:KerbratPierre...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:FargeotPierre...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:RocheHenriHlld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:VeyretCorinne...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:ClaverePierre...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:LevyChristell...lld:pubmed
pubmed-article:17054108pubmed:authorpubmed-author:ChevallierBer...lld:pubmed
pubmed-article:17054108pubmed:copyrightInfo(c) 2006 American Cancer Society.lld:pubmed
pubmed-article:17054108pubmed:issnTypePrintlld:pubmed
pubmed-article:17054108pubmed:day1lld:pubmed
pubmed-article:17054108pubmed:volume107lld:pubmed
pubmed-article:17054108pubmed:ownerNLMlld:pubmed
pubmed-article:17054108pubmed:authorsCompleteYlld:pubmed
pubmed-article:17054108pubmed:pagination2535-44lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:meshHeadingpubmed-meshheading:17054108...lld:pubmed
pubmed-article:17054108pubmed:year2006lld:pubmed
pubmed-article:17054108pubmed:articleTitleInflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.lld:pubmed
pubmed-article:17054108pubmed:affiliationDepartment of Medical Oncology, Henri Becquerel Center, Rouen, France. cveyret@rouen.fnclcc.frlld:pubmed
pubmed-article:17054108pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17054108pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:17054108pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17054108lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17054108lld:pubmed